Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Acromegaly:~* Male or female patients ≥18 years of age~* Acromegaly currently treated with Sandostatin LAR~NET:~* Male or female patients ≥18 years of age~* Functional, well-differentiated (Grade 1 or Grade 2) NET with symptoms of carcinoid syndrome (number of bowel movements and/or flushing)~* Currently treated with Sandostatin LAR for symptom control~Exclusion Criteria:~Acromegaly:~* Inadequate bone marrow function~* Abnormal coagulation or chronic treatment with warfarin or coumarin derivates~* Impaired liver, cardiac and/or renal function~* Known gallbladder, bile duct disease or pancreatitis~* Diabetes with poorly controlled blood glucose levels despite adequate therapy~* Hypothyroidisms not adequately treated~NET:~* Poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, pancreatic islet cell carcinoma, insulinoma, glucagonoma, gastrinoma, goblet cell carcinoid, typical and atypical lung carcinoids, large cell neuroendocrine carcinoma and small cell carcinoma~* Carcinoid syndrome refractory to treatment with conventional doses of somatostatin analogues (SSAs)~* Inadequate bone marrow function~* Abnormal coagulation or chronic treatment with warfarin or coumarin derivates~* Impaired liver, cardiac and/or renal function~* Known gallbladder, bile duct disease or pancreatitis~* Short-bowel syndrome~* Diabetics with poorly controlled blood glucose levels despite adequate therapy~* Hypothyroidism, not adequately treated

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CAM2029 10 mg (NET) (Type: EXPERIMENTAL): CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks
- CAM2029 20 mg (NET) (Type: EXPERIMENTAL): CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly
- CAM2029 10 mg (Acromegaly) (Type: EXPERIMENTAL): CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks
- CAM2029 20 mg (Acromegaly) (Type: EXPERIMENTAL): CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly

Based on this trial design, predict the completion outcome and termination type (if applicable).